Sunflower Pharmaceutical Group Co.,Ltd (SHE: 002737)
China
· Delayed Price · Currency is CNY 20.90
-0.25 (-1.18%)
Sep 9, 2024, 1:47 PM CST
Sunflower Pharmaceutical Group Co.,Ltd Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 5,182 | 5,686 | 5,083 | 4,454 | 3,457 | 4,369 | Upgrade
|
| Other Revenue | 11.49 | 14.62 | 11.03 | 6.55 | 4.83 | 2.5 | Upgrade
|
| Revenue | 5,194 | 5,700 | 5,095 | 4,461 | 3,462 | 4,371 | Upgrade
|
| Revenue Growth (YoY) | -11.66% | 11.89% | 14.20% | 28.86% | -20.81% | -2.24% | Upgrade
|
| Cost of Revenue | 2,374 | 2,493 | 2,157 | 1,822 | 1,450 | 1,830 | Upgrade
|
| Gross Profit | 2,820 | 3,208 | 2,938 | 2,639 | 2,012 | 2,541 | Upgrade
|
| Selling, General & Admin | 1,615 | 1,839 | 1,751 | 1,643 | 1,192 | 1,651 | Upgrade
|
| Research & Development | 132.85 | 128.65 | 94.61 | 132.07 | 113.56 | 118.25 | Upgrade
|
| Other Operating Expenses | 95.37 | 60.82 | 69.4 | 65.56 | 51.03 | 61.6 | Upgrade
|
| Operating Expenses | 1,842 | 2,024 | 1,916 | 1,867 | 1,350 | 1,839 | Upgrade
|
| Operating Income | 977.76 | 1,184 | 1,022 | 771.33 | 661.92 | 702.19 | Upgrade
|
| Interest Expense | -2.29 | -5.97 | -9.73 | -10.19 | -7.39 | -12.14 | Upgrade
|
| Interest & Investment Income | 70.6 | 85.35 | 30.56 | 44.09 | 29.02 | 25.07 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.16 | -0.09 | 0.11 | - | - | -0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.54 | -2.42 | -4.56 | -0.24 | -0.8 | -7.23 | Upgrade
|
| EBT Excluding Unusual Items | 1,047 | 1,260 | 1,039 | 805 | 682.74 | 707.87 | Upgrade
|
| Impairment of Goodwill | - | - | -15.83 | -27.22 | -36.73 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -16.39 | -16.39 | -19.31 | 2.67 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.32 | 3.23 | 7.43 | 47.77 | -5.41 | 3.51 | Upgrade
|
| Asset Writedown | -0.48 | -0.48 | -10.6 | -2.46 | -1.97 | -1.72 | Upgrade
|
| Other Unusual Items | 146.22 | 108.02 | 80.63 | 68.76 | 128.2 | 68.31 | Upgrade
|
| Pretax Income | 1,179 | 1,355 | 1,081 | 894.51 | 766.83 | 777.97 | Upgrade
|
| Income Tax Expense | 176.81 | 189.83 | 171.37 | 132.16 | 146.89 | 142.86 | Upgrade
|
| Earnings From Continuing Operations | 1,002 | 1,165 | 909.73 | 762.35 | 619.94 | 635.11 | Upgrade
|
| Minority Interest in Earnings | -35 | -45.8 | -42.51 | -57.61 | -35.48 | -69.69 | Upgrade
|
| Net Income | 967.32 | 1,119 | 867.22 | 704.74 | 584.45 | 565.42 | Upgrade
|
| Net Income to Common | 967.32 | 1,119 | 867.22 | 704.74 | 584.45 | 565.42 | Upgrade
|
| Net Income Growth | -12.39% | 29.05% | 23.06% | 20.58% | 3.37% | 0.38% | Upgrade
|
| Shares Outstanding (Basic) | 586 | 583 | 586 | 582 | 584 | 583 | Upgrade
|
| Shares Outstanding (Diluted) | 586 | 583 | 586 | 582 | 584 | 583 | Upgrade
|
| Shares Change (YoY) | -0.37% | -0.52% | 0.61% | -0.35% | 0.27% | -0.65% | Upgrade
|
| EPS (Basic) | 1.65 | 1.92 | 1.48 | 1.21 | 1.00 | 0.97 | Upgrade
|
| EPS (Diluted) | 1.65 | 1.92 | 1.48 | 1.21 | 1.00 | 0.97 | Upgrade
|
| EPS Growth | -12.07% | 29.73% | 22.31% | 21.00% | 3.09% | 1.04% | Upgrade
|
| Free Cash Flow | 253.51 | 740.52 | 1,822 | 746.92 | 957.14 | 607.09 | Upgrade
|
| Free Cash Flow Per Share | 0.43 | 1.27 | 3.11 | 1.28 | 1.64 | 1.04 | Upgrade
|
| Dividend Per Share | 1.500 | 1.500 | 1.000 | 0.700 | 0.350 | 1.000 | Upgrade
|
| Dividend Growth | 50.00% | 50.00% | 42.86% | 100.00% | -65.00% | 0% | Upgrade
|
| Gross Margin | 54.29% | 56.27% | 57.67% | 59.15% | 58.12% | 58.13% | Upgrade
|
| Operating Margin | 18.82% | 20.76% | 20.07% | 17.29% | 19.12% | 16.06% | Upgrade
|
| Profit Margin | 18.62% | 19.63% | 17.02% | 15.80% | 16.88% | 12.93% | Upgrade
|
| Free Cash Flow Margin | 4.88% | 12.99% | 35.77% | 16.74% | 27.65% | 13.89% | Upgrade
|
| EBITDA | 1,130 | 1,356 | 1,285 | 935.8 | 811.07 | 851.72 | Upgrade
|
| EBITDA Margin | 21.75% | 23.79% | 25.22% | 20.98% | 23.43% | 19.48% | Upgrade
|
| D&A For EBITDA | 151.77 | 172.35 | 262.65 | 164.47 | 149.15 | 149.54 | Upgrade
|
| EBIT | 977.76 | 1,184 | 1,022 | 771.33 | 661.92 | 702.19 | Upgrade
|
| EBIT Margin | 18.82% | 20.76% | 20.07% | 17.29% | 19.12% | 16.06% | Upgrade
|
| Effective Tax Rate | 15.00% | 14.01% | 15.85% | 14.77% | 19.16% | 18.36% | Upgrade
|
| Revenue as Reported | 5,194 | 5,700 | 5,095 | 4,461 | 3,462 | 4,371 | Upgrade
|
| Advertising Expenses | - | 1,078 | 1,068 | 115.37 | 127.86 | 146.07 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.